Slide 1: Investor Presentation
Investor Presentation November 2010
Slide 2: Safe Harbor
Safe Harbor Certain statements in this presentation concerning our future growth prospects are forward- looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking state
Slide 3: Introduction, Operations, Strategy and R&D Pipeline, Financials
Introduction Operations Strategy and R&D Pipeline Financials Page 2
Slide 4: Biocon is an emerging global biopharmaceutical enterprise
Biocon is an emerging global biopharmaceutical enterprise with products and research services that span the entire drug value chain: pre-clinical discovery to clinical development through to commercialization. Introduction Page 3
Slide 5: Snapshot
Snapshot Incorporation 1978 Initial public offering 2004 (BSE &NSE (India) Patent portfolio 182 patents granted Headquarters Bangalore, India Global reach ~ 75 countries Workforce 5200 employees (10% PhDs) Market capitalisation ~INR 8500+ crore | USD 1.8 bn FY10 Earnings Revenue INR 2405 crore | USD
Slide 6: Business structure, holdings
Business structure, holdings 61% | Promoters 7% | Employees & ESOP trust Syngene International Ltd, India | 100% Custom research, drug discovery 32% | Public Biocon Clinigene International Ltd, India | 100% Clinical development Biocon Research, India | 100% R&D Biocon Biopharmaceuticals Pvt Ltd | 10
Slide 7: Operations
Introduction Strategy and R&D Pipeline Financials
Slide 8: Unique bio-pharma business model
Unique bio-pharma business model Operations Page 7
Slide 9: Capabilities – manufacturing
Capabilities – manufacturing Biocon Active ingredients Aseptic – fill & finish Classic fermentation Cartridges, Vials (Lyophilized), PFS Microbial fermentation* * Asia’s largest manufacturer of Pichia-based products. Mammalian fermentation * Commercialized the world’s first Pichia-derived r-human in
Slide 10: Products
Products Biocon Novel Biologics Biosimilar MAbs Generic APIs Statins Biosimilar Proteins Immunosuppressants Insulin Insulin Analogues Operations Page 9
Slide 11: Strategy and R&D Pipeline
Introduction Operations Strategy and R&D Pipeline Financials
Slide 12: Challenging times ahead for industry
Challenging times ahead for industry Strategy and R&D Pipeline Page 11
Slide 13: Biologics expected to restore growth
Biologics expected to restore growth Strategy and R&D Pipeline Page 12
Slide 14: Our growth strategy aligns with emerging trends
Our growth strategy aligns with emerging trends Strategy and R&D Pipeline Page 13 17
Slide 15: The India Advantage - Research Services
The India Advantage - Research Services Syngene Preclinical, drug R&D Chemistry services Biology, Pharmaceutical biologics services services Synthetic chemistry Early biology Formulation Medicinal chemistry Preclinical development Process R&D Biologics/custom Regulatory consulting Polymer chemistry
Slide 16: The India Advantage - Research Services
The India Advantage - Research Services Clinigene Clinical Research Clinical trials management India's first CAP, NABL accredited Clinical development clinical research labs. Central lab ISO 15189:2003 accredited for Clinical data management quality and competence. Bio-analytical research lab Human
Slide 17: Branded Formulations - India
Branded Formulations - India Brand folio 36 key brands across four therapeutic segments Launched two divisions Q2 FY11 – Immunotherapy and Comprehensive Care Field force – 900 Strategy and R&D Pipeline Page 16
Slide 18: “Pharmerging” markets offer great potential
“Pharmerging” markets offer great potential Rising GDP | Improving health care access | Stronger regulation Russia Poland Ukraine Pakistan Turkey China S Korea Mexico Egypt India Vietnam Venezuela Brazil Bangladesh Thailand Indonesia Chile South Africa Argentina Biocon is an early mover into many of
Slide 19: Global partnerships for Biosimilars
Global partnerships for Biosimilars Insulin and Insulin analogs Monoclonal anti-bodies Strategy and R&D Pipeline Page 18
Slide 20: Biosimilars partnership - Pfizer
Biosimilars partnership - Pfizer Insulin and Insulin analogs Combines Biocon's research and manufacturing capabilities with Pfizer's global marketing prowess Global agreement for the Pfizer will have exclusive Biocon will be commercialization of rights, with some responsible for clinical Biocon's bi
Slide 21: Biosimilars partnership - Mylan
Biosimilars partnership - Mylan Monoclonal Antibodies (MAb) Combines Biocon's R&D and manufacturing of novel biologics/bio-generics with Mylan’s regulatory and commercialization capabilities in the US and Europe Exclusive Mylan and Biocon to Mylan will have Biocon and Mylan to collaboration for shar
Slide 22: Other global alliances - R&D
Other global alliances - R&D Strategy and R&D Pipeline Page 21
Slide 23: Global alliances – Amylin
Global alliances – Amylin Strategy and R&D Pipeline Page 22
Slide 24: Global alliances – Vaccinex
Global alliances – Vaccinex Strategy and R&D Pipeline Page 23
Slide 25: Global alliances – IATRICa
Global alliances – IATRICa Strategy and R&D Pipeline Page 24
Slide 26: Global alliances – Optimer Pharmaceuticals
Global alliances – Optimer Pharmaceuticals Strategy and R&D Pipeline Page 25
Slide 27: R&D pipeline – Biosimilars and Novels
R&D pipeline – Biosimilars and Novels Strategy and R&D Pipeline Page 26
Slide 28: Lead program: Oral insulin IN-105
Lead program: Oral insulin IN-105 Conjugated peptide Lower immunogenicity and mitogenicity. Monotherapy. Comparable safety and good clearance profile. Combination therapy with metformin, Metabolically equivalent. sulfonylurea, PPAR agonists, DPP4i. Pre-meal insulin in combination with basal insulins
Slide 29: Anti-CD6 MAb : T1h
Anti-CD6 MAb : T1h Target CD6 o.4mg/kg once in 4 weeks is a type 1 cell membrance glycoprotein belonging to the scavenger receptor cysteine-rich (SRCR) superfamily group B. CD6 is predominantly expressed by T cells & a B cell subset. Day 1 Day 29 CD6 binds ALCAM (activated leukocyte cell adhesion mo
Slide 30: Financials
Introduction Strategy and R&D Pipeline Financials
Slide 31: Revenue, profit
Revenue, profit INR crore / USD mn FY07 FY08 FY09 FY10 Revenue 990 220 1090 273 1673 364 2405 512 EBITDA 287 63 335 83 388 84 509 108 Net profit* 200 44 225 56 240 52 293 62 INR Crore/ USD mn Q2 FY11 H1 FY11 Revenue 688 150 1360 294 Rev growth 16% EBITDA 153 33 293 63 EBITDA Margin 22% 22% Net Profi
Slide 32: Revenue mix: group
Revenue mix: group 29% 38% 38% 13% 11% 11% 11% 55% 48% 49% INR crore / USD million FY09 FY10 H1 FY11 Biopharma products* 915 199 1175 250 673 146 Research services 225 49 281 60 150 32 Others 54 12 37 8 18 4 FY09 and FY10: Avg.exch.rate in that fiscal Sub Total 1194 260 1493 317 841 182 H1FY11: USD
Slide 33: Revenue mix: segmental
Revenue mix: segmental Approximate percentages ; as of 30 September 2010 Financials Page 32
Slide 34: Biopharma mix: Segmental roadmap
Biopharma mix: Segmental roadmap Approximate percentages Financials Page 33
Slide 35: Thank you
Thank you